Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary tupaia hepatocytes

Hepatology

Volumn 41, Issue 2, 2005, Pages 247-256

  Baumert, Thomas F ^a   Yang, Chun ^a   Schürmann, Peter ^a   Köck, Josef ^a   Ziegler, Christian ^a   Grüllich, Carsten ^a   Nassal, Michael ^a   Liang, T Jake ^b   Blum, Hubert E ^a   Von Weizsäcker, Fritz ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL TRANSFORMATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCANDENTIA; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; CELLS, CULTURED; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; MUTATION; PROMOTER REGIONS (GENETICS); TRANSDUCTION, GENETIC; TUPAIA;

EID: 19944430257     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20553     Document Type: Article

References (50)

1. Baumert TF, Blum HE. Hepatitis B virus mutations: molecular biology and clinical relevance. Vir Hep Rev 2000;6:177-192.
2. Pumpens P, Grens E, Nassal M. Molecular epidemiology and immunology of hepatitis B virus infection - an update. Intervirology 2002;45:218-232.
3. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. HEPATOLOGY 2003;37:19-26.
4. Bartholomeusz A, Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. HEPATOLOGY 2001;34:432-435.
5. Günther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-137.
6. Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003;77:6601-6612.
7. Zollner B, Petersen J, Puchhammer-Stockl E, Kleczmayr J, Sterneck M, Fischer L, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. HEPATOLOGY 2004;39:42-50.
8. Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-248.
9. Baumert TF, Liang TJ. Precore mutants revisited. HEPATOLOGY 1995;23:184-186.
10. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996;98:2268-2276.
11. Pult I, Chouard T, Wieland S, Klemenz R, Yaniv M, Blum HE. A hepatitis B virus mutant with a new hepatocyte nuclear factor 1 binding site emerging in transplant-transmitted fulminant hepatitis B. HEPATOLOGY 1997;25:1507-1515.
12. Laskus T, Rakela J, Nowicki MJ, Persing DH. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 1995;109:1618-1623.
13. Günther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H. Type, prevalence, and significance of core promoter / enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 1996;70:8318-8331.
14. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994;68:8102-8110.
15. Buckwold VE, Xu Z, Chen M, Yen TSB, Ou J-H. Effects of a naturally occuring mutation in the hepatitis B virus basal core promotor on precore gene expression and viral replication. J Virol 1996;70:5845-5851.
16. Preikschat P, Gunther S, Reinhold S, Will H, Budde K, Neumayer HH, et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. HEPATOLOGY 2002;35:466-477.
17. Raney AK, Johnson JL, Palmer CNA, McLachlan A. Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promotor. J Virol 1997;71:1058-1071.
18. Liang TJ, Hasegawa H, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-1709.
19. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994;68:1651-1659.
20. Baumert TF, Marrone A, Vergalla J, Liang TJ. Naturally occurring mutations define a novel function of the hepatitis B virus core promotor in core protein expression. J Virol 1998;72:6785-6795.
21. Pang QF, Liu JC, Wan XB, Qiu FX, Xu AY. Experimental infection of adult Tupaia belangen yunalis with human rotavirus. Chin Med J (Engl) 1983;96:85-94.
22. Darai G, Schwaier A, Komitowski D, Munk K. Experimental infection of Tupaia belangeri (tree shrews) with herpes simplex virus types 1 and 2. J Infect Dis 1978;137:221-226.
23. Zhao X, Tang ZY, Klumpp B, Wolff-Vorbeck G, Barth H, Levy S, et al. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest 2002;109:221-232.
24. Xie Z-C, Riezu-Boi J-I, Lasarte J-J, Guillen J, Su J-H, Civeira M-P, et al. Transmission of hepatitis C virus infection to tree shrews. Virology 1998;244:513-520.
25. Köck J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsäcker F. Efficient infection of primary Tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001;75:5084-5089.
26. Ren S, Nassal M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary Tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol 2001;75:1104-1116.
27. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003;77:9511-9521.
28. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Nad Acad Sci U S A 1998;95:2509-2514.
29. Walter E, Keist R, Niederöst B, Pult I, Blum HE. Hepatitis B virus infection of Tupaia hepatocytes in vitro and in vivo. HEPATOLOGY 1996;24:1-5.
30. Köck J, Baumert TF, Blum HE, von Weizsäcker F. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary Tupaia hepatocytes. HEPATOLOGY 2003;37:1410-1418.
31. Huang J, Liang TJ. A novel hepatitis B virus (HBV) genetic element with rev response element-like properties that is essential for expression of HBV gene products. Mol Cell Biol 1993;13:7476-7486.
32. Grüllich C, Sullards MC, Fuks Z, Merrill AH Jr, Kolesnick R. CD95(Fas/APO-1) signals ceramide generation independent of the effector stage of apoptosis. J Biol Chem 2000;275:8650-8656.
33. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neutons in Parkinson's disease. Proc Natl Acad Sci U S A 2000;97:2875-2880.
34. Zhou Z, Sun X, Kang YJ. Ethanol-induced apoptosis in mouse liver: Fas-and cytochrome c-mediated caspase-3 activation pathway. Am J Pathol 2001;159:329-338.
35. Jia LT, Zhang LH, Yu CJ, Zhao J, Xu YM, Gui JH, et al. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 2003;63:3257-3262.
36. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, et al. Adenoviral gene transfer of rumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003;63:2369-2372.
37. Lenhoff RJ, Summers J. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. J Virol 1994;68:5706-5713.
38. Lenhoff RJ, Luscombe CA, Summers J. Competition in vivo between a cytopathic variant and a wild-type duck hepatitis B virus. Virology 1998;251:85-95.
39. Lenhoff RJ, Luscombe CA, Summers J. Acute liver injury following infection with a cytopathic strain of duck hepatitis B virus. HEPATOLOGY 1999;29:563-571.
40. Bruss V. Revisiting the cytopathic effect of hepatitis B virus infection. HEPATOLOGY 2002;36:1327-1329.
41. Foo NC, Ahn BY, Ma X, Hyun W, Yen TS. Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein. HEPATOLOGY 2002;36:1400-1407.
42. Su F, Theodosis CN, Schneider RJ. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J Virol 2001;75:215-225.
43. Kim KH, Seong BL. Pro-apoptotic function of HBVX protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J 2003;22:2104-2116.
44. Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C, et al. The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc Natl Acad Sci U S A 1997;94:8162-8167.
45. Prevot D, Darlix JL, Ohlmann T. Conducting the initiation of protein synthesis: the tole of eIF4G. Biol Cell 2003;95:141-156.
46. Nevins TA, Harder ZM, Kotneluk RG, Holcik M. Distinct regulation of internal ribosome entry site-mediated translation following cellular stress is mediated by apoptotic fragments of eIF4G translation initiation factor family members eIF4GI and p97/DAP5/NAT1. J Biol Chem 2003;278:3572-3579.
47. Marissen WE, Lloyd RE. Eukaryotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells. Mol Cell Biol 1998;18:7565-7574.
48. Oren I, Hershow RC, Ben-Porath E, Krivoy N, Goldstein N, Rishpon S, et al. A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Med 1989;110:691-698.
49. Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 2003;100:7797-7802.
50. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.